[6] Phase III ACHIEVE-1 trial [edit] In April 2025, results from a phase III clinical trial involving 559 people with type 2 diabetes who took an oral orforglipron pill or a placebo daily for 40 weeks showed that orforglipron produced a reduction of hemoglobin A1C level by 1.3 to 1.6 percentage points from a starting level of 8%
What is the process like
The journey becomes about overall health improvement rather than a single number on the scale, encouraging long-term consistency and better outcomes
Insights into the authentic active ingredients and action sites of oral exogenous glutathione in the treatment of ischemic brain injury based on pharmacokinetic-pharmacodynamic studies
4.3.1 Available evidence for natural pregnancy rates and TTP Published meta-analytic summaries and follow-up data from individual trials suggest that GLP-1RA-based metabolic optimization may be associated with higher natural conception rates and shorter time to pregnancy in selected overweight or obese women with PCOS (111, 112, 124)
Nature 499 , 444449 (2013) Wootten, D., Simms, J., Miller, L